# SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

> **NCT05160896** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 90 (estimated)

## Conditions studied

- Advanced Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Raltitrexed
- **DRUG:** Irinotecan
- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05160896
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-12
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160896, "SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05160896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*